PD1-IL2

Unknown Manufacturer

Generate AI report

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

BIFUNCTIONAL MOLECULE FORMED BY FUSION OF PD1 ANTIBODY AND INTERLEUKIN 2
EP 4471068 A4Applicant: INST BIOPHYSICS CASPriority: 2022
CN
EP
US
WO
5 publications
METHODS OF TREATING CANCER WITH A COMBINATION OF ADOPTIVE CELL THERAPY AND A TARGETED IMMUNOCYTOKINE
EP 4611771 A1Applicant: REGENERON PHARMAPriority: 2022
CN
EP
US
WO
4 publications
METHODS OF TREATING CANCER WITH A COMBINATION OF A PD1 INHIBITOR AND A TARGETED IMMUNOCYTOKINE
EP 4791504 A1Applicant: REGENERON PHARMAPriority: 2023
CN
EP
US
WO
4 publications
METHODS OF TREATING CANCER WITH A COMBINATION OF A TAAXCD3 BISPECIFIC ANTIBODY AND A TARGETED IMMUNOCYTOKINE
EP 4791777 A1Applicant: REGENERON PHARMAPriority: 2023
CN
EP
US
WO
4 publications
靶向NY-ESO-1的T细胞受体联合表达PD1抗体可变区及其用途
CN 108864276 BApplicant: 上海恒润达生生物科技股份有限公司Priority: 2017
CN
靶向CD19的嵌合抗原受体及联合表达抗PD1抗体可变区的方法和及其用途
CN 108864286 BApplicant: 上海恒润达生生物科技股份有限公司Priority: 2017
CN
一种靶向HER2联合表达PD1-MICA融合蛋白的嵌合抗原受体及其表达载体和应用
CN 110684121 BApplicant: 华夏源(上海)细胞基因工程股份有限公司Priority: 2019
CN
一种靶向B细胞成熟抗原的嵌合抗原受体及其应用
CN 110669144 BApplicant: 华夏源(上海)细胞基因工程股份有限公司Priority: 2019
CN
一种靶向HER2的嵌合抗原受体及其表达载体和应用
CN 110684119 BApplicant: 华夏源(上海)细胞基因工程股份有限公司Priority: 2019
CN
一种靶向CD19的T细胞抗原耦合器及其表达载体和应用
CN 110684118 BApplicant: 华夏源(上海)细胞基因工程股份有限公司Priority: 2019
CN

Drugs